Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
High doses of calcium (> 1.5 mg/day) and calcitriol (> 2.5 μg/day) were necessary in 3 patients despite ongoing teriparatide, in order to maintain normal calcium levels and control the clinical symptoms associated with hypocalcemia.
Source: Baseline characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Observational study.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Meta-analysis unclear · Open-label reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1 to 84) treatment
Source: Article title.
It is a multicenter, observational, retro-prospective, open label study.
Source: Abstract.
Patients were excluded if they had other pathologies or drugs interfering with bone metabolism, or in case of contraindications as described in the technical data sheet [].
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1 to 84) treatment
Observational study · Journal of Endocrinological Investigation · 2022
Original publication title
Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1 to 84) treatment
© The Author(s) 2022, , corrected publication 2022
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
The main purpose of this study was to investigate the effects of 12 months of rhPTH (1 to 84) (Natpar®) treatment in a cohort of patients selected according to the indications of hypoparathyroidism guidelines. The use of recombinant human PTH (1 to 84) [rhPTH (1 to 84)] is approved as hormonal replacement therapy in patients with hypoparathyroidism not adequately controlled with conventional therapy.
Source: PurposeAbstract: What methods does the paper describe?
It is a multicenter, observational, retro-prospective, open label study. Eleven Italian Endocrinological centers, members of Hypoparathyroidism Working Group of the Italian Society of Endocrinology (HypoparaNET) were involved. Main outcome measures were serum and urinary calcium and phosphate concentration, calcium-phosphate product, renal function, oral calcium and vitamin D doses, and clinical manifestations.
Source: MethodsAbstract: Results
Fourteen adult subjects, affected by chronic hypoparathyroidism, were treated with rhPTH (1 to 84) for 12 months. At 12 months of rhPTH (1 to 84) treatment, 61.5% of patients discontinued calcium supplement and 69.2% calcitriol. Mean albumin-adjusted total serum calcium levels quickly normalized after initiation of rhPTH (1 to 84) treatment compared to baseline (p = 0.009), remaining in the normal range until 12 months. Rare hypo-hypercalcemia episodes were reported. Renal function was maintained normal and no renal complications were reported. Serum and urinary phosphate and urinary calcium were maintained in the normal range.
Mean phosphatemia levels linearly decreased from 3 months up to 12 months compared to baseline (p = 0.014). No severe adverse events were described.
Source: ResultsAbstract: Conclusions
Biochemical and clinical results confirm the efficacy and safety of rhPTH (1 to 84) therapy, which represents an important option for hypoparathyroid patients unresponsive to conventional therapy.
Source: ConclusionsAuthors’ abstract
Purpose
The main purpose of this study was to investigate the effects of 12 months of rhPTH (1 to 84) (Natpar®) treatment in a cohort of patients selected according to the indications of hypoparathyroidism guidelines. The use of recombinant human PTH (1 to 84) [rhPTH (1 to 84)] is approved as hormonal replacement therapy in patients with hypoparathyroidism not adequately controlled with conventional therapy.
Methods
It is a multicenter, observational, retro-prospective, open label study. Eleven Italian Endocrinological centers, members of Hypoparathyroidism Working Group of the Italian Society of Endocrinology (HypoparaNET) were involved. Main outcome measures were serum and urinary calcium and phosphate concentration, calcium-phosphate product, renal function, oral calcium and vitamin D doses, and clinical manifestations.
Results
Fourteen adult subjects, affected by chronic hypoparathyroidism, were treated with rhPTH (1 to 84) for 12 months. At 12 months of rhPTH (1 to 84) treatment, 61.5% of patients discontinued calcium supplement and 69.2% calcitriol. Mean albumin-adjusted total serum calcium levels quickly normalized after initiation of rhPTH (1 to 84) treatment compared to baseline (p = 0.009), remaining in the normal range until 12 months. Rare hypo-hypercalcemia episodes were reported. Renal function was maintained normal and no renal complications were reported. Serum and urinary phosphate and urinary calcium were maintained in the normal range.
Mean phosphatemia levels linearly decreased from 3 months up to 12 months compared to baseline (p = 0.014). No severe adverse events were described.
Conclusions
Biochemical and clinical results confirm the efficacy and safety of rhPTH (1 to 84) therapy, which represents an important option for hypoparathyroid patients unresponsive to conventional therapy.
Publication and source details
Original title: Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1 to 84) treatment
G. Marcucci; G. Beccuti; G. Carosi; F. Cetani; L. Cianferotti; A. M. Colao; C. Di Somma; M. Duradoni; A. Elefante; L. Ghizzoni; M. Giusti; A. G. Lania; E. Lavezzi; B. Madeo; G. Mantovani; C. Marcocci; L. Masi; S. Parri; F. Pigliaru; A. Santonati; A. Spada; L. Vera; M. L. Brandi
Journal of Endocrinological Investigation · 2022
© The Author(s) 2022, , corrected publication 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T09:33:13.415312+00:00
DOI: 10.1007/s40618-022-01800-y · PMC9360119